Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
PATIENT ENROLLMENT COMPLETED IN THE REAL-WORLD STUDY OF OT-703 IN HAINAN BOAO

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

Reference is made to the announcement of the Company dated May 13, 2025 in relation to the approved real world study of OT-703.

The board (the "**Board**") of directors of the Company is pleased to announce that one of the Group's products, OT-703 (ILUVIEN®, fluocinolone intravitreal implant), an injectable, non-biodegradable fluocinolone acetate intravitreal implant for the treatment of diabetic macular edema (DME), has recently completed the enrollment of a total of 195 patients for the real-world study in Boao Lecheng International Medical Tourism Pilot Zone (博鰲樂城國際醫療旅遊先行區) in Hainan Province, in People's Republic of China.

OT-703, namely the 190 microgram fluocinolone acetonide intravitreal implant in applicator (0.19 mg), is an injectable, non-biodegradable fluocinolone acetate intravitreal implant and used for treatment of DME by continuously releasing a microdose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. It has received the regulatory approval from the United States Food and Drug Administration (FDA) and marketed under the trade name "ILUVIEN®". It is the only FDA-approved corticosteroid intraocular implant for the treatment of DME with a three-year sustained-release period. In April 2021, the Company and Alimera Sciences, Inc. ("**Alimera**") entered into an exclusive license agreement, pursuant to which the Company obtained the exclusive licensed rights from Alimera in relation to the development and commercialization of ILUVIEN® in Greater China, South Korea and 11 countries in Southeast Asia. In December 2023, OT-703 obtained an approval from the Pharmacy and Poisons Board of Hong Kong for its registration as a pharmaceutical product in Hong Kong in accordance with the Pharmacy and Poisons Ordinance (Cap. 138 of the Laws of Hong Kong).

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-703 (ILUVIEN®) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, January 20, 2026

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.